Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24333908 | 0.99 | NPSR1 (0.56) | POLBMEN1KMT2ANPSR1CYP1A2 | |
| SCHEMBL17199590 | 0.86 | KDM4E (0.58) | POLBMEN1KMT2AKDM4EHSD17B10 | |
| SCHEMBL21347706 | 0.86 | KMT2A (0.66) | MEN1KMT2ACYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL26506323 | 0.86 | MEN1 (0.53) | POLBMEN1KMT2ANPSR1CYP1A2 | |
| SCHEMBL13164063 | 0.86 | NPSR1 (0.58) | POLBMEN1KMT2ANPSR1CYP1A2 | |
| SCHEMBL11484492 | 0.85 | MEN1 (0.57) | POLBMEN1KMT2ANPSR1CYP1A2 | |
| SCHEMBL21883951 | 0.85 | MEN1 (0.52) | POLBMEN1KMT2ANPSR1CYP1A2 | |
| SCHEMBL13164061 | 0.84 | NPSR1 (0.59) | POLBMEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL2964718 | 0.84 | IKBKB (0.57) | POLBMEN1KMT2ANPSR1CYP1A2 | |
| SCHEMBL20879965 | 0.84 | MEN1 (0.54) | POLBMEN1KMT2ANPSR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| US-11357828-B2 | Releasable GLP-1 conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2022-06-14 | — | — | US | disclosed |
| EP-3592393-B1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| WO-2020053815-A1 | RELEASABLE GLP-1 CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2020-03-19 | — | — | WO | disclosed |
| WO-2019171358-A1 | RELEASABLE ANTIBODY CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | POLB 1863/4885MEN1 2694/4885KMT2A 4144/4885 |
| US-11357828-B2 | Releasable GLP-1 conjugates | GLP1R, GIPR, IAPP | POLB 4810/4885MEN1 279/4885KMT2A 4392/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | POLB 1863/4885MEN1 2694/4885KMT2A 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.